MEDIFAST INC

Medifast's OPTAVIA program highlighted its strong clinical evidence, based on peer-reviewed randomized controlled trials and gold-standard DXA body composition measurements. The company emphasized that its program achieved 98% lean mass retention and a 14% reduction in visceral fat at 16 weeks. Coach-supported clients also lost significantly more weight and fat compared to self-directed groups, positioning OPTAVIA as a scientifically rigorous option in the rapidly expanding weight loss market, valued at $31.07 billion in 2025 and projected to exceed $45 billion by 2030.

Medifast's OPTAVIA announced its program effectively addresses metabolic shifts in women during perimenopause and menopause, focusing on visceral fat reduction and lean mass preservation. Clinical research shows the Optimal Weight 5 & 1 Plan reduces visceral fat by 14% in 16 weeks and retains 98% lean mass. The company emphasizes the critical role of coaching, with coached participants losing significantly more weight and fat.

Medifast, Inc. announced the resignation of Jason L. Groves, Esq., its Chief Legal Officer & Corporate Secretary, effective May 29, 2026. Mr. Groves and the company entered into a separation agreement, providing him with a one-time severance payment equal to one month of his base salary. The company stated that his departure was not due to any disagreements and has initiated a search for a permanent replacement.

Medifast, Inc. announced the appointment of Nicholas Johnson as its new Chief Executive Officer, effective June 1, 2026. He succeeds Daniel Chard, who will transition to non-executive Chairman of the Board. Johnson's compensation package includes a $600,000 base salary and a 69% increase in total target compensation. Additionally, stockholders approved an amendment to the 2012 Share Incentive Plan, increasing authorized shares by 250,000, and ratified the appointment of RSM US LLP as the independent auditor.

OPTAVIA, Medifast's coach-guided metabolic health system, announced research findings validating the significant impact of human coaching on weight management outcomes. A randomized controlled trial showed clients on the OPTAVIA Optimal Weight 5 & 1 Plan® with coaching lost up to 10 times more weight and 17 times more fat than those without support. The company emphasizes that structured human support, accountability, and real-time emotional guidance from certified coaches are crucial for higher retention and more significant weight loss, addressing the challenge of high dropout rates in weight management programs. Independent research also indicates that 96% of Americans recognize the need for lifestyle changes for weight loss, but only 17% feel confident doing it alone, highlighting the value of OPTAVIA's coaching model.

Medifast's OPTAVIA system, a science-backed, coach-guided metabolic health program, demonstrates superior clinical outcomes compared to app-only weight management programs. Research indicates that human support and accountability are crucial for sustained engagement and better results, with 70% of app users discontinuing within 100 days. OPTAVIA participants working with a coach achieved significantly greater weight and fat loss, along with improved body composition, including a 14% reduction in visceral fat and 98% lean mass retention.

Medifast's OPTAVIA program is highlighted for its science-backed, coach-guided approach to metabolic health, focusing on quality weight loss through visceral fat reduction and lean mass preservation. Clinical research, including 18 randomized controlled trials, supports the program's effectiveness, showing participants on the Optimal Weight 5 & 1 Plan® achieved a 14% reduction in visceral fat and retained 98% of lean mass. The program also emphasizes the significant role of coaching, with participants losing up to 10 times more weight and 17 times more fat with coach support.

Medifast announced that its OPTAVIA metabolic health system is clinically validated by extensive peer-reviewed research, including 18 randomized controlled trials. The company highlighted the importance of randomized controlled trials for proving program efficacy, emphasizing that OPTAVIA's Optimal Weight 5 & 1 Plan helps preserve 98% of lean mass over 16 weeks. Additionally, the data shows that clients utilizing OPTAVIA coaches achieve significantly better weight and fat loss outcomes compared to those without coaching support.

Medifast reported a significant decline in Q1 2026 financial results, with revenue falling to $76.04 million and net loss increasing to $2.12 million. The company is executing a strategic transformation, focusing on holistic metabolic health and leveraging its coach-guided lifestyle system. It also completed the sale of its Maryland Distribution Center, generating a $2.2 million gain.

Medifast reported a significant decline in its first quarter 2026 financial results, with revenue decreasing 34.3% to $76.0 million and net loss widening to $2.1 million, or $(0.19) per diluted share. The company saw a 44.9% reduction in active earning coaches, primarily due to client acquisition challenges and GLP-1 medication adoption. Despite these declines, Medifast noted a second consecutive quarter of year-over-year coach productivity growth and maintained a strong balance sheet with $168.9 million in cash and no debt. The company provided a cautious outlook, projecting Q2 2026 revenue between $60 million and $80 million and a full-year 2026 revenue range of $270 million to $300 million, with expected losses for both periods.